Shin-cheh C. Chen

Linkou Branch
Taoyuan, TNQ, Taiwan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 96 publications

SERENA-6 visual patient-reported outcomes & safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy.

SERENA-6 visual patient-reported outcomes & safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy.

Journal: The oncologist

Published: May 22, 2026

SERENA-6 visual patient-reported outcomes and safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy.

SERENA-6 visual patient-reported outcomes and safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy.

Journal: The oncologist

Published: May 22, 2026

2025 Update of the Taiwan Expert Consensus on Hormone Receptor-Positive Metastatic Breast Cancer Management.

2025 Update of the Taiwan Expert Consensus on Hormone Receptor-Positive Metastatic Breast Cancer Management.

Journal: Journal of breast cancer

Published: April 09, 2026

Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer.

Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer.

Journal: The New England journal of medicine

Published: December 10, 2025

Preliminary efficacy and safety of pembrolizumab combined with chemotherapy as neoadjuvant therapy for advanced temporal bone squamous cell carcinoma

Preliminary efficacy and safety of pembrolizumab combined with chemotherapy as neoadjuvant therapy for advanced temporal bone squamous cell carcinoma

Journal: Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery

Published: December 02, 2025

Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer.

Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 26, 2025

Clinical Scenarios Using Thoracodorsal and Lateral Thoracic Vessels Versus Internal Mammary Vessels in Bipedicled Deep Inferior Epigastric Perforator Flap Breast Reconstruction: A Comparative Study.

Clinical Scenarios Using Thoracodorsal and Lateral Thoracic Vessels Versus Internal Mammary Vessels in Bipedicled Deep Inferior Epigastric Perforator Flap Breast Reconstruction: A Comparative Study.

Journal: Journal of reconstructive microsurgery

Published: October 28, 2025

Application of CTC-derived spheroid for drug screening toward personalized treatment in patients with breast cancer.

Application of CTC-derived spheroid for drug screening toward personalized treatment in patients with breast cancer.

Journal: Translational oncology

Published: June 18, 2025

DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer.

DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 12, 2025

First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer.

First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer.

Journal: The New England journal of medicine

Published: June 02, 2025

ASO Author Reflections: Nipple-Sparing Mastectomy with Single Axillary Incision: A Safe Approach to Hide the Scar.

ASO Author Reflections: Nipple-Sparing Mastectomy with Single Axillary Incision: A Safe Approach to Hide the Scar.

Journal: Annals of surgical oncology

Published: December 11, 2024

Real-world outcomes of everolimus-based treatment in a Taiwanese cohort with metastatic HR+/HER2- breast cancer.

Real-world outcomes of everolimus-based treatment in a Taiwanese cohort with metastatic HR+/HER2- breast cancer.

Journal: Journal of the Chinese Medical Association : JCMA

Published: November 11, 2024

Showing 1-12 of 96

Last Updated: 09/26/2026